Hummel Kristin, Richards William
Department of Surgery, University of South Alabama College of Medicine, Mastin Building, 2451 Fillingim Street, Mobile, AL 36617, USA.
Department of Surgery, University of South Alabama College of Medicine, Mastin Building, 2451 Fillingim Street, Mobile, AL 36617, USA.
Surg Clin North Am. 2015 Jun;95(3):653-67. doi: 10.1016/j.suc.2015.02.016.
Multiple new endoluminal devices and therapies have been devised to create a more effective antireflux barrier in patients with gastroesophageal reflux disease (GERD). Most of these therapies have been abandoned, because they were ineffective and/or had significant adverse effects. However, there are currently two therapies (Stretta, EsophyX) that have US Food and Drug Administration approval and continue to be used in select patients with GERD. The clinical management of GERD, disease complications, endoluminal techniques, evidence for efficacy, and controversies concerning endoluminal therapy for GERD are reviewed and discussed.
已经设计出多种新型腔内装置和疗法，以在胃食管反流病（GERD）患者中创建更有效的抗反流屏障。这些疗法大多已被摒弃，因为它们无效和/或有显著的不良反应。然而，目前有两种疗法（Stretta、EsophyX）已获得美国食品药品监督管理局的批准，并继续用于特定的GERD患者。本文对GERD的临床管理、疾病并发症、腔内技术、疗效证据以及关于GERD腔内治疗的争议进行了综述和讨论。
